Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martina Bebin

Showing results (41-50 of 116) with videos related to

Pageof 12
Sort By:
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|April 21, 2018
Visual and semi-automatic non-invasive detection of interictal fast ripples: A potential biomarker of epilepsy in children with tuberous sclerosis complexDanilo Bernardo, Hiroki Nariai, Shaun A Hussain, et al.
Epilepsy & Behavior : E&B|May 27, 2019
fMRI study of cannabidiol-induced changes in attention control in treatment-resistant epilepsyJane B Allendorfer, Rodolphe Nenert, E Martina Bebin, et al.
Clinical Pharmacology and Therapeutics|August 31, 2021
Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatment-Resistant EpilepsyBrittney H Davis, T Mark Beasley, Michelle Amaral, et al.
Pediatric Neurology|August 3, 2021
Epilepsy Is Heterogeneous in Early-Life Tuberous Sclerosis ComplexS Katie Z Ihnen, Jamie K Capal, Paul S Horn, et al.
Epilepsia|October 29, 2024
Accumulated seizure burden predicts neurodevelopmental outcome at 36 months of age in patients with tuberous sclerosis complexS Katie Z Ihnen, Samuel Alperin, Jamie K Capal, et al.
Pediatrics|November 5, 2017
Presentation and Diagnosis of Tuberous Sclerosis Complex in InfantsPeter E Davis, Rajna Filip-Dhima, Georgios Sideridis, et al.
JAMA Neurology|December 21, 2020
Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical TrialElizabeth A Thiele, E Martina Bebin, Hari Bhathal, et al.
Plos One|September 8, 2018
Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosisJohn J Bissler, Norio Nonomura, Klemens Budde, et al.
Annals of Neurology|April 29, 2014
UBQLN2 mutation causing heterogeneous X-linked dominant neurodegenerationAkl C Fahed, Barbara McDonough, Cynthia M Gouvion, et al.
Computers in Biology and Medicine|May 6, 2026
A two-step temporal data augmentation and supervised learning framework for predicting autism diagnosis at 36 months in patients with tuberous sclerosis complexCancan Zhang, Runqiu Wang, Jamie K Capal, et al.
Pageof 12

Showing results (41-50 of 116) with videos related to

Sort By:
Pageof 12
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|April 21, 2018
Visual and semi-automatic non-invasive detection of interictal fast ripples: A potential biomarker of epilepsy in children with tuberous sclerosis complexDanilo Bernardo, Hiroki Nariai, Shaun A Hussain, et al.
Epilepsy & Behavior : E&B|May 27, 2019
fMRI study of cannabidiol-induced changes in attention control in treatment-resistant epilepsyJane B Allendorfer, Rodolphe Nenert, E Martina Bebin, et al.
Clinical Pharmacology and Therapeutics|August 31, 2021
Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatment-Resistant EpilepsyBrittney H Davis, T Mark Beasley, Michelle Amaral, et al.
Pediatric Neurology|August 3, 2021
Epilepsy Is Heterogeneous in Early-Life Tuberous Sclerosis ComplexS Katie Z Ihnen, Jamie K Capal, Paul S Horn, et al.
Epilepsia|October 29, 2024
Accumulated seizure burden predicts neurodevelopmental outcome at 36 months of age in patients with tuberous sclerosis complexS Katie Z Ihnen, Samuel Alperin, Jamie K Capal, et al.
Pediatrics|November 5, 2017
Presentation and Diagnosis of Tuberous Sclerosis Complex in InfantsPeter E Davis, Rajna Filip-Dhima, Georgios Sideridis, et al.
JAMA Neurology|December 21, 2020
Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical TrialElizabeth A Thiele, E Martina Bebin, Hari Bhathal, et al.
Plos One|September 8, 2018
Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosisJohn J Bissler, Norio Nonomura, Klemens Budde, et al.
Annals of Neurology|April 29, 2014
UBQLN2 mutation causing heterogeneous X-linked dominant neurodegenerationAkl C Fahed, Barbara McDonough, Cynthia M Gouvion, et al.
Computers in Biology and Medicine|May 6, 2026
A two-step temporal data augmentation and supervised learning framework for predicting autism diagnosis at 36 months in patients with tuberous sclerosis complexCancan Zhang, Runqiu Wang, Jamie K Capal, et al.
Pageof 12